Search

everythinglearnresearchcommunity

for

Search:↓

Middle-aged and elderly men with BPH had higher hospitalization rates for COVID-19.

Possible link between androgens and COVID-19 severity; more research needed.

Men's sensitivity to male hormones might affect how severe COVID-19 gets for them.

The letter is skeptical about the effectiveness of anti-androgen therapy for COVID-19 and calls for strong evidence from clinical trials.

Spironolactone may help reduce COVID-19 severity in men by blocking harmful effects of certain hormones.

Antiandrogens may help prevent or treat COVID-19 by blocking virus entry into cells.

The document suggests that more research is needed to confirm if baldness can indicate a higher risk of severe COVID-19 in men.

Male hormones like testosterone may make COVID-19 worse, and testing for sensitivity to these hormones could help predict how severe a patient's symptoms might be. Treatments that reduce these hormones are being explored.

A certain genetic variant in the androgen receptor may predict the severity of COVID-19 in men.

Male pattern hair loss could hint at androgens affecting COVID-19 severity.

Low testosterone may increase COVID-19 severity in men.

Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.

Men with more CAG repeats in the androgen receptor gene and lower testosterone levels may experience more severe COVID-19.

The conclusion is that individual differences in COVID-19 severity are influenced by factors like age, sex, race, and genetics, which are important for personalized medicine.

Betacoronaviruses, like COVID-19, may cause hormone system dysfunction and affect disease susceptibility and severity.

Women with high androgen levels may have more severe COVID-19 symptoms.

Anti-androgens might help reduce COVID-19 severity in men.

COVID-19 may worsen symptoms of benign prostatic hyperplasia (BPH).

COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.

Skin problems in COVID-19 patients are rare and may be due to the body's complex immune response or blood clotting issues.

The letter suggests testosterone replacement therapy might worsen COVID-19 outcomes.

Wait 3 months after COVID-19 before trying assisted reproduction and further research is needed on COVID-19's effects on male hormones and fertility.

Men are more likely to have severe respiratory viral infections like COVID-19 due to hormonal and genetic differences, while women generally have stronger immune responses.

Certain skin rashes can indicate COVID-19 severity, with chilblains-like rashes linked to milder cases and livedoid patterns to more severe cases.

Sex hormones may affect COVID-19 severity, with estrogen possibly reducing risk and testosterone potentially increasing it.

Sex hormones may influence COVID-19 severity, with males at higher risk, and certain hormone therapies could potentially treat the virus.

Most COVID-19 patients in hospitals have androgenetic alopecia, more in men, suggesting a link between androgen sensitivity and severe COVID-19 symptoms.

Men with higher androgen levels may have severe COVID-19 symptoms, but those on antiandrogen therapy are less likely to contract the virus and have milder symptoms. Anti-androgen drugs could potentially treat COVID-19, but more research is needed.

Androgens play a key role in causing alopecia by changing the hair growth cycle.

The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.